Jason C. Bermak, MD, PhD, is a board-certified psychiatrist, also with a PhD in pharmacology and toxicology. He has a private practice and additionally serves as the medical director of SF-CARE, Inc., a small clinical research center located in San Rafael. Dr. Bermak’s clinical trials are currently focused on developing novel treatments and treatment combinations for those suffering from conditions of depression, anxiety, and schizophrenia. These new treatments include the use nasal spray formulations of ketamine for depression and novel long-acting antipsychotics for psychosis.
Dr. Bermak’s clinical duties are currently outpatient focused and have, in recent years, also included institutional and inpatient positions at the California Medical Facility, Napa State Hospital, and Saint Francis Memorial Hospital.
Dr. Bermak is also a partner at Anvyl Pharmaceuticals, LLC, a non-commercial biopharmaceutical company aimed at developing therapies for neurocognitive and psychiatric disorders. He has authored or coauthored more than a dozen publications stemming from his CNS and drug development-related research endeavors. He received his psychiatric residency training at the University of California, San Francisco, his MD and PhD in pharmacology at the University of California, Irvine, and a BS in Chemistry at the University of California, Berkeley.